On the other hand, hypogammaglobulinemic patients, especially IgA, those on lymphoma or myeloma treatment, especially with monoclonal antibodies, heavily treated patients, and those who are close to HSCT are the ones who are less likely to respond to vaccination and should receive prophylactic monoclonal antibodies against SARS-CoV-2. This evidence concerns the gene CD79A and lymphoma.